Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus LOW QUEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus LOW QUEL.
ENSKYCE vs LOW-QUEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
10 mg orally twice daily; not to exceed 20 mg/day.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive